{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicynrxgpfq6duspnep3v7zivkk7r2r42x2x4j4gp7myryboentrhu",
    "uri": "at://did:plc:3mn56v4dlq26elsetrrjnhbg/app.bsky.feed.post/3mjijv2gyv6l2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidcmxyarhzpatpve4mgsk5mwkpd6237wlopiqywf32ejc7fa5itwq"
    },
    "mimeType": "image/png",
    "size": 18055
  },
  "path": "/johnson-johnson-starts-2026-on-firm-footing-as-drug-growth-offsets-a-more-measured-medtech-pace/",
  "publishedAt": "2026-04-14T21:34:36.000Z",
  "site": "https://www.core-brief.com",
  "textContent": "A raised full-year sales outlook, stronger adjusted earnings and continued momentum in oncology and immunology kept Johnson & Johnson’s growth story intact, even as revenue eased modestly from the prior quarter.\n\n## 📌 Key Takeaways\n\nJohnson & Johnson opened 2026 with a solid, if not flawless, quarter. First-quarter sales",
  "title": "Johnson & Johnson Starts 2026 on Firm Footing as Drug Growth Offsets a More Measured MedTech Pace"
}